Assessment of Dengue virus helicase and methyltransferase as targets for fragment-based drug discovery.
暂无分享,去创建一个
Gérard Bricogne | Changqing Li | Bruno Coutard | Andrew Sharff | A. Sharff | B. Coutard | G. Bricogne | E. Decroly | J. Lescar | Julien Lescar | Etienne Decroly | Karine Barral | K. Barral | Changqing Li
[1] Jd Landes,et al. Recent Developments in J Ic Testing , 1977 .
[2] Dennis E. Hruby,et al. Novel Benzoxazole Inhibitor of Dengue Virus Replication That Targets the NS3 Helicase , 2013, Antimicrobial Agents and Chemotherapy.
[3] Rob Leurs,et al. Transforming fragments into candidates: small becomes big in medicinal chemistry. , 2009, Drug discovery today.
[4] E. Mancini,et al. Crystal Structure of a Novel Conformational State of the Flavivirus NS3 Protein: Implications for Polyprotein Processing and Viral Replication , 2009, Journal of Virology.
[5] David C. Chang,et al. Correction: Rational Design of a Live Attenuated Dengue Vaccine: 2′-O-Methyltransferase Mutants Are Highly Attenuated and Immunogenic in Mice and Macaques , 2013, PLoS Pathogens.
[6] Jean-Louis Romette,et al. An RNA cap (nucleoside‐2′‐O‐)‐methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization , 2002, The EMBO journal.
[7] A. Hopkins,et al. Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.
[8] Lawrence C Kuo. Fragment-based drug design - tools, practical approaches, and examples. Preface. , 2011, Methods in enzymology.
[9] Martino Bolognesi,et al. Flaviviral methyltransferase/RNA interaction: Structural basis for enzyme inhibition , 2009, Antiviral Research.
[10] Jürgen Bajorath,et al. Molecular Scaffolds with High Propensity to Form Multi-Target Activity Cliffs , 2010, J. Chem. Inf. Model..
[11] Amr H. Mahmoud,et al. Integrated structure-based activity prediction model of benzothiadiazines on various genotypes of HCV NS5b polymerase (1a, 1b and 4) and its application in the discovery of new derivatives. , 2012, Bioorganic & medicinal chemistry.
[12] C. Abad-Zapatero,et al. Ligand efficiency indices for effective drug discovery , 2007, Expert opinion on drug discovery.
[13] Jack Snoeyink,et al. Nucleic Acids Research Advance Access published April 22, 2007 MolProbity: all-atom contacts and structure validation for proteins and nucleic acids , 2007 .
[14] P. Shi,et al. Ligand-Bound Structures of the Dengue Virus Protease Reveal the Active Conformation , 2011, Journal of Virology.
[15] Clemens Vonrhein,et al. Data processing and analysis with the autoPROC toolbox , 2011, Acta crystallographica. Section D, Biological crystallography.
[16] D. Rodbard,et al. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. , 1978, The American journal of physiology.
[17] P. Shi,et al. Crystal Structure of the Dengue Virus Methyltransferase Bound to a 5′-Capped Octameric RNA , 2010, PloS one.
[18] Ding-Shinn Chen,et al. Structure-based discovery of triphenylmethane derivatives as inhibitors of hepatitis C virus helicase. , 2009, Journal of medicinal chemistry.
[19] Louise Thauvette,et al. Discovery of a novel series of non-nucleoside thumb pocket 2 HCV NS5B polymerase inhibitors. , 2013, Bioorganic & medicinal chemistry letters.
[20] R. Walsh,et al. A microassay for ATPase. , 1988, Analytical biochemistry.
[21] Chris Abell,et al. Fragment-based approaches to enzyme inhibition. , 2007, Current opinion in biotechnology.
[22] E. Decroly,et al. Structural and functional analysis of methylation and 5'-RNA sequence requirements of short capped RNAs by the methyltransferase domain of dengue virus NS5. , 2007, Journal of molecular biology.
[23] X. de Lamballerie,et al. The 2C putative helicase of echovirus 30 adopts a hexameric ring-shaped structure. , 2010, Acta crystallographica. Section D, Biological crystallography.
[24] Ramyavardhanee Chandrasekaran,et al. A Crystal Structure of the Dengue Virus Non-structural Protein 5 (NS5) Polymerase Delineates Interdomain Amino Acid Residues That Enhance Its Thermostability and de Novo Initiation Activities* , 2013, The Journal of Biological Chemistry.
[25] P. Chène,et al. Towards the design of flavivirus helicase/NTPase inhibitors: crystallographic and mutagenesis studies of the dengue virus NS3 helicase catalytic domain. , 2006, Novartis Foundation symposium.
[26] Jean-Louis Romette,et al. A Structural Basis for the Inhibition of the NS5 Dengue Virus mRNA 2′-O-Methyltransferase Domain by Ribavirin 5′-Triphosphate* , 2004, Journal of Biological Chemistry.
[27] Hongping Dong,et al. Flavivirus methyltransferase: a novel antiviral target. , 2008, Antiviral research.
[28] David Beer,et al. Ten years of dengue drug discovery: progress and prospects. , 2013, Antiviral research.
[29] M. Karelson,et al. Fragment-based development of HCV protease inhibitors for the treatment of hepatitis C. , 2012, Current computer-aided drug design.
[30] David I. Stuart,et al. Structure and functionality in flavivirus NS-proteins: Perspectives for drug design , 2010, Antiviral research.
[31] Alicia M. Hanson,et al. Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug. , 2012, The Journal of antimicrobial chemotherapy.
[32] Randy J. Read,et al. Phaser crystallographic software , 2007, Journal of applied crystallography.
[33] P. Emsley,et al. Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.
[34] Peter Güntert,et al. Structure-guided fragment-based in silico drug design of dengue protease inhibitors , 2011, J. Comput. Aided Mol. Des..
[35] Masaki Tomimoto,et al. Fragment-based discovery of hepatitis C virus NS5b RNA polymerase inhibitors. , 2008, Bioorganic & medicinal chemistry letters.
[36] Stephen J. Thomas,et al. Current issues in dengue vaccination , 2013, Current opinion in infectious diseases.
[37] S. Vasudevan,et al. Flexibility between the Protease and Helicase Domains of the Dengue Virus NS3 Protein Conferred by the Linker Region and Its Functional Implications , 2010, The Journal of Biological Chemistry.
[38] Jie Luo,et al. Retrieval of Crystallographically-Derived Molecular Geometry Information , 2004, J. Chem. Inf. Model..
[39] Hongping Dong,et al. 2′-O methylation of the viral mRNA cap evades host restriction by IFIT family members , 2010, Nature.
[40] Thomas Mendgen,et al. Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry. , 2012, Journal of medicinal chemistry.
[41] Brett A Tounge,et al. Ligand efficiency and fragment-based drug discovery. , 2009, Drug discovery today.
[42] Gang Wang,et al. Small Molecule Inhibitors That Selectively Block Dengue Virus Methyltransferase* , 2010, The Journal of Biological Chemistry.
[43] M. McCoy,et al. Non-peptidic small-molecule inhibitors of the single-chain hepatitis C virus NS3 protease/NS4A cofactor complex discovered by structure-based NMR screening. , 2004, Journal of medicinal chemistry.
[44] P. Hajduk,et al. A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.
[45] Amy D. Fung,et al. Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B. , 2013, Journal of medicinal chemistry.
[46] A. Thompson,et al. Analysis of flavivirus NS5 methyltransferase cap binding. , 2009, Journal of molecular biology.
[47] K. Murthy,et al. Modulation of the Nucleoside Triphosphatase/RNA Helicase and 5′-RNA Triphosphatase Activities of Dengue Virus Type 2 Nonstructural Protein 3 (NS3) by Interaction with NS5, the RNA-dependent RNA Polymerase* , 2005, Journal of Biological Chemistry.
[48] E. Decroly,et al. Biochemical characterization of the (nucleoside-2'O)-methyltransferase activity of dengue virus protein NS5 using purified capped RNA oligonucleotides (7Me)GpppAC(n) and GpppAC(n). , 2010, The Journal of general virology.
[49] Subhash G. Vasudevan,et al. Structure of the Dengue Virus Helicase/Nucleoside Triphosphatase Catalytic Domain at a Resolution of 2.4 Å , 2005, Journal of Virology.
[50] C. Murray,et al. The rise of fragment-based drug discovery. , 2009, Nature chemistry.
[51] Michèle N Schulz,et al. MTSA--a Matlab program to fit thermal shift data. , 2013, Analytical biochemistry.
[52] A. M. Giannetti,et al. De novo fragment design: a medicinal chemistry approach to fragment-based lead generation. , 2013, Journal of medicinal chemistry.
[53] S. Vasudevan,et al. Crystal structure of the NS3 protease-helicase from dengue virus , 2008 .
[54] Tomas Lundqvist. The devil is still in the details--driving early drug discovery forward with biophysical experimental methods. , 2005, Current opinion in drug discovery & development.
[55] Hongping Dong,et al. Biochemical and genetic characterization of dengue virus methyltransferase. , 2010, Virology.
[56] G. Maga,et al. The RNA helicase, nucleotide 5'-triphosphatase, and RNA 5'-triphosphatase activities of Dengue virus protein NS3 are Mg2+-dependent and require a functional Walker B motif in the helicase catalytic core. , 2004, Virology.
[57] J. Nettleship,et al. Methods for protein characterization by mass spectrometry, thermal shift (ThermoFluor) assay, and multiangle or static light scattering. , 2008, Methods in molecular biology.
[58] Mike Cherry,et al. Introduction to Fragment‐Based Drug Discovery , 2008 .
[59] Burkhard Ludewig,et al. Ribose 2′-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5 , 2011, Nature Immunology.
[60] R. Charrel,et al. Comparative Production Analysis of Three Phlebovirus Nucleoproteins under Denaturing or Non-Denaturing Conditions for Crystallographic Studies , 2011, PLoS neglected tropical diseases.
[61] Amedeo Caflisch,et al. Flaviviral protease inhibitors identified by fragment-based library docking into a structure generated by molecular dynamics. , 2009, Journal of medicinal chemistry.
[62] Anthony M Giannetti,et al. Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors. , 2008, Journal of medicinal chemistry.
[63] Jan Schultz,et al. Integration of fragment screening and library design. , 2007, Drug discovery today.
[64] P. Evans,et al. Scaling and assessment of data quality. , 2006, Acta crystallographica. Section D, Biological crystallography.
[65] B. Coutard,et al. Development of specific dengue virus 2'-O- and N7-methyltransferase assays for antiviral drug screening. , 2013, Antiviral research.
[66] D. Scott,et al. Fragment-based approaches in drug discovery and chemical biology. , 2012, Biochemistry.
[67] R. Bartenschlager,et al. Synthesis and biological evaluation of α-ketoamides as inhibitors of the Dengue virus protease with antiviral activity in cell-culture. , 2011, Bioorganic & medicinal chemistry.
[68] David Beer,et al. Discovery of a Non-Peptidic Inhibitor of West Nile Virus NS3 Protease by High-Throughput Docking , 2009, PLoS neglected tropical diseases.
[69] M. Congreve,et al. Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.
[70] L. Kuo,et al. Fragment-based drug design : tools, practical approaches, and examples , 2011 .